The new medicine of DNA repair pathways: damage repair vulnerabilities in cancer

Loss of DNA repair pathways is an early and frequent event in tumorigenesis. DNA repair-deficient cancers often become critically dependent on backup DNA repair pathways, which present an “Achilles heel” that can be targeted to eliminate cancer cells. This is the basis of synthetic lethality and is exemplified by the success of poly(ADP-ribose) polymerase (PARP) inhibitors in treating BRCA-deficient breast and ovarian cancers. However, new therapeutic strategies are urgently needed to overcome acquired and innate PARP inhibitor resistance and to exploit other DNA repair deficiencies. This online event will discuss the discovery, development, success and clinical challenges of PARP inhibitors and the current efforts to develop new DNA repair inhibitors to exploit other vulnerabilities in cancer. 

Speakers include ​​​Dr Graeme Smith (Artios Pharma), Prof Charlie Gourley (The University of Edinburgh), Prof Ruth Plummer (Newcastle University), Dr Michael Zinda (Repare Therapeutics) and Ms Kate Bingham (SV Health Investors).

This event will run as an online Zoom webinar. Please register for your free place. All registrants will receive Zoom joining details by email in advance of the webinar.